MS Speaks

The Overview section of the report on Ocrevus that is part of a larger report entitled  LiverTox: Clinical and Research Information on Drug-Induced Liver Injury, issued by the National Institute of Diabetes and Digestive and Kidney Diseases. This section was last updated in July 2018.

https://www.ncbi.nlm.nih.gov/books/NBK548145/#Ocrelizumab.OVERVIEW


The "likelihood score" for Ocrevus is E*, which is defined as:

Category E*. The drug is suspected to be capable of causing liver injury or idiosyncratic acute liver injury but there have been no convincing cases in the medical literature. In some situations cases of acute liver injury have been reported to regulatory agencies or mentioned in large clinical studies of the drug, but the specifics and details supportive of causality assessment are not available. The agent is unproven, but suspected to cause liver injury.